ProMIS Neurosciences reports positive early safety and biomarker results for Alzheimer’s trial
ProMIS Neurosciences reported positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Phase 1b trial of PMN310 in patients with mild cognitive impairment due to Alzheimer’s disease or mild AD. In a blinded analysis of 136 patients, the company reports no cases of amyloid
<p>ProMIS Neurosciences reported positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Phase 1b trial of PMN310 in patients with mild cognitive impairment due to Alzheimer’s disease or mild AD. In a blinded analysis of 136 patients, the company reports no cases of amyloid</p>